Catalog No.
EQB86202
Expression system
Mammalian Cells
Species
Canis lupus familiaris (Dog) (Canis familiaris)
Protein length
Asn2183-Gln2341
Predicted molecular weight
46.29 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
O18806
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Coagulation factor VIII, Procoagulant component, F8
Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk., PMID:39233012
Hemophilia A in a litter of Border Collies caused by a one base pair deletion in the F8 gene., PMID:38104983
A frameshift deletion in F8 associated with hemophilia A in Labrador Retriever dogs., PMID:37438956
A SINE Insertion in F8 Gene Leads to Severe Form of Hemophilia A in a Family of Rhodesian Ridgebacks., PMID:33494213
Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A., PMID:32425925
Successful liver transplant from a hemophilia A donor with no development of hemophilia A in recipient., PMID:31997485
Advances and challenges for hemophilia gene therapy., PMID:31332444
Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs., PMID:27011017
Turoctocog alfa (NovoEight®)--from design to clinical proof of concept., PMID:24797664
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants., PMID:20852129
Gene therapy for hemophilia A. Friend or foe?, PMID:19542881
Indirect carrier detection of canine haemophilia A using factor VIII microsatellite markers., PMID:18454805
Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data., PMID:16926139
The leak stops here: platelets as delivery vehicles for coagulation factors., PMID:16823486
Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII., PMID:12098087
Studies to detect carriers of haemophilia A in German shepherd dogs using diagnostic DNA polymorphisms in the human factor VIII gene., PMID:9125358
Separation of the antihemophilic factor (F. 8) from fibrinogen with thrombin and manganese chloride., PMID:5937693
ANTIBODY TO ANTIHEMOPHILIC FACTOR AND ITS LACK OF REACTION WITH HEMOPHILIC PLASMA., PMID:14264741
PURIFICATION OF ANTIHEMOPHILIC FACTOR (FACTOR VIII) BY AMINO ACID PRECIPITATION., PMID:14167116
ANTIHEMOPHILIC FACTOR IN CROSS-CIRCULATED NORMAL AND HEMOPHILIC DOGS., PMID:14120438
A study of the separation of fibrinogen and antihemophilic factor (AHF) in canine, porcine, and human plasmas., PMID:13569420
Antihemophilic factor (AHF): plasma levels after administration of AHF preparations to hemophilic dogs., PMID:13485042
Utilization of the antihemophilic factor during clotting of canine blood and plasma., PMID:14819291
For research use only. Not for human or drug use.
